David F. McDermott, MD

Articles by David F. McDermott, MD

Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
View More
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
Brian Rini, MD, FASCORoundtable | December 8, 2023
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
David F. McDermott, MDUromigos Live 2023 | November 6, 2023
Dr. David McDermott from Beth Israel Deaconess Medical Center discusses his favorite Uromigos guests and episodes.